Goal 3: Advance Translational Research

Submitted by (@nhlbiforumadministrator)

Maximizing Previous Investment in Existing Cohorts

Everyone would like to see integration of genomic, metabolomic, epigenomic, proteomic, transcriptomic, etc. data analyzed in the context of clinical disease, environmental influences, and even end-organ effects (lung versus heart or blood as an example). Rarely can this occur on small cohorts, but rarely are funds available to take maximum use of existing large cohorts and the samples and information collected within ...more »

Voting

22 net votes
34 up votes
12 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@chintamani.atreya)

Tools to facilitate availability and safe use of innovative blood products and their analogs

Novel blood products are being developed based on innovative science (e.g., ex vivo manufactured RBC and platelets, and platelet and plasma derived hemostatic products). However, there is a significant lag in the development of appropriate tools and model systems, which poses a challenge when evaluating such products for regulatory approval.

Voting

12 net votes
17 up votes
5 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@wheeze)

Heterogeneity in Asthma Phenotypes

As the current chair of the Research and Training Division, I would like to convey that the AAAAI membership would like the NHLBI to consider the following in the development of its strategic plan: Asthma appears to be due to heterogenous etiologies. ┬áTo better characterize the various phenotypes and potential etiologies, it would be important to create more epidemiologic and biomarker focused databases, which could ...more »

Voting

-12 net votes
6 up votes
18 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@wheeze)

Biomarkers and Response Predictors in Asthma

As the current chair of the Research and Training Division, I would like to convey that the AAAAI membership would like the NHLBI to consider the following in the development of its strategic plan: Given the development of specific biologic therapy for asthma, what are the biomarkers and predictors of response that will allow clinicians to choose the best therapeutic combination of medications (biologic and otherwise) ...more »

Voting

7 net votes
18 up votes
11 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@scottsimon)

Detection of inflammatory monocytes as a biomarker of CVD

Coronary artery disease (CAD), of which atherosclerosis is a major contributor, costs the United States $108.9 billion each year. While a number of conventional risk factors such as smoking, diabetes and hypertension have been associated with CAD, their predictive performance is poor in the prevention of acute coronary syndrome (ACS). Despite the prevalence of ACS in our society, there are currently no molecular biomarkers ...more »

Voting

-6 net votes
8 up votes
14 down votes
Active